Form 4: Merit Medical Systems Inc. Executive Brian G. Lloyd Reports Stock Transactions

Brian G. Lloyd, Chief Legal Officer and Secretary of Merit Medical Systems Inc., reports acquisition and disposal of company stock and stock options.

Summary

• Brian G. Lloyd, Chief Legal Officer and Secretary of Merit Medical Systems Inc., filed a Form 4 detailing changes in beneficial ownership.
• On February 27, 2025, Lloyd acquired 11,533 shares of common stock related to performance stock units and surrendered 4,198 shares for payroll taxes at a price of $98.5.
• On February 28, 2025, Lloyd acquired 7,056 restricted stock units (RSUs) and exercised 25,000 non-qualified stock options at $44.8, then sold 25,000 shares at a weighted average price of $99.5.
• Following these transactions, Lloyd directly owns 38,993 shares of Merit Medical Systems Inc.
• Lloyd also holds non-qualified stock options for a total of 78,063 shares at various exercise prices and expiration dates.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions appear to be part of a standard compensation plan with both acquisitions and disposals of shares. The acquisition of shares due to performance metrics is a positive sign.

Positives

• The acquisition of 11,533 shares due to the achievement of performance stock unit conditions suggests positive company performance.
• The grant of 7,056 restricted stock units indicates continued confidence in the executive's role and future contributions.

Negatives

• The sale of 25,000 shares could be interpreted negatively, although it may be for personal financial management.

Risks

• Executive stock sales can sometimes signal a lack of confidence, although this is not necessarily the case here.
• Changes in executive compensation structures could impact future stock transactions.

Future Outlook

The vesting schedule of the RSUs and the exercisability of stock options suggest continued alignment of executive incentives with company performance over the next several years.

Industry Context

Executive stock transactions are common and closely monitored in the medical device industry to gauge management's confidence and alignment with shareholder interests.

Comparison to Industry Standards

• Executive compensation structures, including stock options and RSUs, are standard practice in the medical device industry, similar to companies like Medtronic, Stryker, and Boston Scientific.
• The vesting schedules and exercise prices of the options are within typical ranges for executive compensation packages in comparable companies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders' perception of the company, depending on how they interpret the stock sale.
• Employees may view the vesting of RSUs as a positive sign of the company's commitment to its executives.

Next Steps

• Monitor future Form 4 filings by Brian G. Lloyd and other executives for further insights into their perspectives on the company's performance.
• Track the vesting of RSUs and the exercise of stock options as they occur.

Key Dates